scholarly journals Immunoradiometric and immunohistochemical analysis of Cathepsin D in ovarian cancer: lack of association with clinical outcome

1998 ◽  
Vol 78 (12) ◽  
pp. 1645-1652 ◽  
Author(s):  
G Ferrandina ◽  
G Scambia ◽  
A Fagotti ◽  
G D'Agostino ◽  
P Benedetti Panici ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Clinical Outcome ◽  
Cathepsin D ◽  
Immunohistochemical Analysis

scholarly journals High Expression of Cathepsin D in Non-Hodgkin’s Lymphomas Negatively Impacts on Clinical Outcome

2010 ◽  
Vol 28 (3) ◽  
pp. 167-183 ◽  
Author(s):  
Giuseppina Nicotra ◽  
Federica Manfroi ◽  
Carlo Follo ◽  
Roberta Castino ◽  
Nicola Fusco ◽  
...  
Keyword(s):  
Clinical Outcome ◽  
Tumor Cells ◽  
Survival Probability ◽  
Cathepsin D ◽  
Rank Test ◽  
Lysosomal Protease ◽  
T Cell Lymphomas ◽  
Kaplan Meier ◽  
Punctate Pattern ◽  
Hodgkin's Lymphomas

The lysosomal protease Cathepsin D (CD) has been implicated in the homeostasis of lymphatic tissues. We investigated whether the level of CD expression influences the progression and the clinical outcome in Non-Hodgkin’s Lymphomas (NHLs). The expression of CD was assessed by immunohistochemistry and immunofluorescence in biopsies of Diffuse Large B Cell Lymphomas (DLBCL, 35 cases), Follicular Lymphomas (FL, 9 cases of grade I-II plus 14 cases of grade IIIB), Chronic Lymphocytic Leukaemias (CLL, 17 cases) and Peripheral T-cell Lymphomas (PTCL, 5 cases). CD staining showed a cytoplasmic punctate pattern compatible with its lysosomal localization. Based on the level of CD expression and the proportion of positive cells, lymphomas were classified as ‘low expressing’ (< 20% of tumor cells) or ‘highly expressing’ (≥ 20% of tumor cells). Lymphomas highly expressing CD were associated with a worse stage (III-IV) at diagnosis (31/34 cases;p= 0.002) and with a poor clinical outcome (i.e., partial remission and death; 28/34 cases;p= 0.03). In the subgroup of aggressive/high grade of malignancy lymphomas (i.e., DLBCL, FL IIIB and PTCL), the Kaplan-Meier curve revealed a very low cumulative overall survival probability (~20% at 5 year) for patients bearing a NHL with > 40% CD-positive cells compared to that of patients bearing a NHL with < 20% CD-positive cells (~70% at 5 year). This correlation was statistically significant (log-rank test,p= 0.01). In Cox multivariate analysis CD failed to be a prognosticator independent of pathologic stage, though the hazard ratio confirmed the association of low expression with a better survival probability. These data indicate that the presence of a high percentage of CD-positive tumor cells negatively reflects on the progression of NHLs.

scholarly journals COL11A1 promotes tumor progression and predicts poor clinical outcome in ovarian cancer

Oncogene ◽  
2013 ◽  
Vol 33 (26) ◽  
pp. 3432-3440 ◽  
Author(s):  
Y-H Wu ◽  
T-H Chang ◽  
Y-F Huang ◽  
H-D Huang ◽  
C-Y Chou
Keyword(s):  
Ovarian Cancer ◽  
Clinical Outcome ◽  
Tumor Progression ◽  
Poor Clinical Outcome

scholarly journals Impact of humoral immune response against p53 on clinical outcome of High-Grade Serous Ovarian Cancer (HGSOC) patients

2016 ◽  
Vol 27 ◽  
pp. viii8
Author(s):  
M. Garziera ◽  
E. Cecchin ◽  
M. Montico ◽  
R. Roncato ◽  
S. Gagno ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Immune Response ◽  
Clinical Outcome ◽  
Humoral Immune Response ◽  
High Grade ◽  
Serous Ovarian Cancer ◽  
Humoral Immune

Expression of dendritic cells in ovarian tumors correlates with clinical outcome in patients with ovarian cancer

2001 ◽  
Vol 32 (8) ◽  
pp. 803-807 ◽  
Author(s):  
Avi Eisenthal ◽  
N. Polyvkin ◽  
L. Bramante–Schreiber ◽  
F. Misonznik ◽  
A. Hassner ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Dendritic Cells ◽  
Clinical Outcome ◽  
Ovarian Tumors

Cathepsin D antigenic epitopes identified by the humoral responses of ovarian cancer patients

1998 ◽  
Vol 46 (1) ◽  
pp. 48-54 ◽  
Author(s):  
Sreenavasa R. Chinni ◽  
C. Gerçel-Taylor ◽  
Gregory E. Conner ◽  
D. D. Taylor
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Cathepsin D ◽  
Humoral Responses ◽  
Antigenic Epitopes

Combined Immunoscore of CD103 and CD3 Identifies Long-Term Survivors in High-Grade Serous Ovarian Cancer

2016 ◽  
Vol 26 (4) ◽  
pp. 671-679 ◽  
Author(s):  
Hans-Christian Bösmüller ◽  
Philipp Wagner ◽  
Janet Kerstin Peper ◽  
Heiko Schuster ◽  
Deborah Lam Pham ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Overall Survival ◽  
Clinical Outcome ◽  
Prognostic Value ◽  
Intraepithelial Lymphocytes ◽  
High Grade ◽  
Serous Ovarian Cancer ◽  
Term Survival ◽  
Cell Counts

ObjectiveIncreased numbers of tumor-infiltrating lymphocytes (TILs) in high-grade serous ovarian cancer (HGSC) are associated with improved clinical outcome. Intraepithelial localization of TILs might be regulated by specific homing receptors, such as CD103, which is widely expressed by intraepithelial lymphocytes. Given the emerging role of CD103+ TILs, we aimed to assess their contribution to the prognostic value of immunoscoring in HGSC.MethodsThe density of intratumoral CD3+ and CD103+ lymphocytes was examined by immunohistochemistry on a tissue microarray of a series of 135 patients with advanced HGSC and correlated with CD4+, CD8+, CD56+, FoxP3+, and TCRγ+ T-cell counts, as well as E-cadherin staining and conventional prognostic parameters and clinical outcome.ResultsBoth the presence of CD103+ cells, as well as high numbers of intraepithelial CD3+ lymphocytes (CD3E), showed a significant correlation with overall survival, in the complete series, as well as in patients with optimal debulking and/or platinum sensitivity. Combining CD3 and CD103 counts improved prognostication and identified 3 major subgroups with respect to overall survival. The most pronounced effect was demonstrated for patients with optimally resected and platinum-sensitive tumors. Patients with CD3high/CD103high tumors showed a 5-year survival rate at 90%, CD3low/CD103high at 63%, and CD3low/CD103low at 0% (P < 0.001).ConclusionsThese results suggest that combined assessment of CD103 and CD3 counts improves the prognostic value of TIL counts in HGSC and might identify patients with early relapse or long-term survival based on the type and extent of the immune response.

Sign in / Sign up

Export Citation Format

Share Document